CTRI/2015/10/006326尚未招募未知
A Multi Center, Open Label, Randomized, Two-Treatment, In Vivo, Crossover, Single Dose, Bioequivalence Study with Pharmacokinetic Endpoints to Compare the Pharmacokinetics of Marketed Product TobraDex® (Containing Tobramycin 0.3% and Dexamethasone 0.1 % Ophthalmic Suspension, Manufactured by Alcon Laboratories, Inc., USA.) to an Investigational Ophthalmic Sterile Suspension (Containing Tobramycin 0.3% and Dexamethasone 0.1%, Manufactured by Cipla Limited, India), in Aqueous Humor of Patients Undergoing Indicated Cataract Surgery - TBO Study
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- Cipla Ltd
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •(1) Men or non-pregnant women of 18 to 65 years of age
- •(2)Presence of visually significant cataracts in both eyes as established by the complete ophthalmologic exam which are accounting for a best corrected visual acuity of 20/40 or worse as measured on Snellen chart or with glare
- •(3) Have a chief complaint consistent with visually significant cataracts such as but not limited to halos and/or glare with vision, difficulty reading, ambulating and or walking
- •(4) Be medically fit with clinically acceptable laboratory profiles
- •(5) Be willing to follow the required pre operative directions and post op care and be able to follow the scheduled appointment
- •(6) Have given the written informed consent for participation in the study
排除标准
- •(1) Participation in any ophthalmic indicative bioavailability/ bioequivalence/ Pharmacokinetic study or received an ophthalmic indicative investigational drug within a period of three months prior to screening
- •(2) Pregnant women or lactating mothers or women planning to become pregnant during the study period
- •(3) Presence or history of epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella of the cornea and conjunctiva
- •(4) History of â??recent (last 15 days)â?? or â??activeâ?? viral diseases of the cornea and conjunctiva. Presence of corneal conditions like but not limited to Keratoconus, Fuchâ??s Dystrophy, S/P PKP, Chronic corneal erosion/ulcers/edema, S/P refractive surgery
- •(5) Presence or history of uveitis or uveitis within the previous 12 months, or laser-assisted in-situ keratomileusis, photorefractive, keratectomy, radial keratotomy, or similar surgery in the previous three months
- •(6) Presence of retinal disorders including but not limited to glaucoma, active diabetic retinopathy, wet/ dry macular degeneration, Histoplasmosis and any other retinal disease that would make vision worse than 20/50 best corrected will be excluded
- •(7) Ocular trauma within past three months of the screening, active external ocular disease, inflammation, or infection (mycobacterial or fungal disease) of the study eye and corneal diseases or disruption
- •(8) Patients who had received topical and or systemic/ oral steroids including but not limited to dexamethasone or beclomethasone within 7 days of screening
- •(9) History of any allergies (e.g. asthma, urticaria) including drug allergies that would place the patient at increased risk, as determined by the investigator(s)
- •(10) Known hypersensitivity or allergy to TobraDex® in combination or its components
- •(11) History of alcohol, chemical, drug abuse or dependence
- •(12) Serologic positivity for the Hepatitis B virus (HBsAg) and Human Immunodeficiency Virus (HIV 1 and 2)
- •(13) Presence of clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, hepatic, immunologic, hematological, endocrine, or nervous system
- •or psychiatric disease or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the patient at increased risk, as determined by the investigator(s)
研究者
相似试验
已完成
3 期
(Pivotal study)PK of TobraDex is compared with Tobramycin 0.3% And Dexamethasone 0.1%(Study drug) W/V In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery.CTRI/2010/091/003008Zumanta Pharmaceuticals LLC552
进行中（未招募）
不适用
Bioequivalence (BE) Study of Pazopanib in subjects with Advanced renal cell carcinoma.CTRI/2020/11/029079Alvogen PB RD LLC
已完成
不适用
Bio equivalent study of Methotrexate tablet 2.5 mg of Eugia Pharma specialites Limited, India with Methotrexate tablets 2.5 mg of Dava Pharmaceuticals Inc, USA in adult patients with mild to severe Psoriasis or Rheumatoid ArthritisCTRI/2016/08/007152Eugia Pharma Specialities Limited A JV of Aurobindo Pharma Limited Celon Laboratories Limited36
已完成
不适用
A Study of Doxorubicin Hydrochloride Liposome Injection in Patients with Ovarian Cancer.CTRI/2018/08/015266Celerity Pharmaceuticals LLC76
已完成
不适用
A Study of Doxorubicin Hydrochloride Injection in Patients with Breast CancerCTRI/2018/08/015325Celerity Pharmaceuticals LLC68